MedTrace Logo

Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910

NCT01961414 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2015-10-30

No results posted yet for this study

Summary

The purpose of this research study is to determine if a "Treat and Extend" regimen (increasing the time between visits when the disease is stable and not getting worse) of aflibercept 2.0mg injections inside the eye for treating patients with Wet Age-related Macular Degeneration.

Conditions

  • Exudative Age-related Macular Degeneration

Interventions

DRUG

Aflibercept

Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits

Sponsors & Collaborators

  • Palmetto Retina Center, LLC

    lead OTHER

Principal Investigators

  • William L. Clark, M.D. · Palmetto Retina Center, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-03-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01961414 on ClinicalTrials.gov